Comparative evaluation of amisulpride and escitalopram on Hamilton anxiety rating scale among depression patients in a tertiary care teaching hospital in Nepal

Vijay Kaul, Shakti B. Dutta, Mirza A. Beg, Shalu Bawa, Mohammed Anjoom, Nand K. Singh, Srihari Dutta

Abstract


Background: Depression is an important global public health problem and is a major cause of disability and premature death. The present study was conducted to compare efficacy and safety of amisulpride and escitalopram on Hamilton anxiety rating scale (HAM-A) among depression patients in a tertiary care teaching hospital in Nepal.

Methods: The study was conducted in patients for 1-year in the Department of Neuropsychiatry, Nepalgunj Medical College and Teaching Hospital. A total of 117 depression patients were divided into two groups. Group I (58 patients) received amisulpride tablet at a dose of 50 mg/day and Group II (59 patients) were given escitalopram at a dose of 10 mg/day. The patients were required to follow-up at 4, 8 and 15 weeks. The efficacy of the drugs was calculated by HAM-A. Adverse drug reactions (ADRs) were monitored at every follow-up. Appropriate statistical tools using Graphpad instat 3.0 were used for analysis p<0.05 was considered significant.

Results: HAM-A score in group receiving amisulpride at 0 and 15 weeks was 19.83±0.33 and 8.17±0.32 (p<0.0001). HAM-A score in group receiving escitalopram at 0 and 15 weeks was 20.76±0.28 and 8.98±0.24 (p<0.0001). Gastrointestinal disturbances, sexual disturbances, amenorrhea, lactation, agitation, and insomnia were the commonly encountered ADRs.

Conclusion: Both amisulpride and escitalopram were highly effective in the treatment of anxiety in depression patients during the study period. Further, more clinical studies with longer follow-up duration are needed to substantiate the therapeutic effects of amisulpride.


Keywords


Depression, Amisulpride, Escitalopram, Hamilton anxiety rating scale

Full Text:

PDF

References


Akiskal HS. Mood disorders: historical introduction and conceptual overview. In: Kaplan and Sadock’s Comprehensive Textbook of Psychiatry. 8th Edition. Philadelphia: Lippincott Williams & Wilkins; 2005: 1559 75.

Ray S, Chogtu B. Prescribing trends in depression: a drug utilization study done at a tertiary healthcare centre. J Clin Diagn Res. 2011;5(3):573-7.

Lopez AD, Mathers CD, Ezzati M, Jamison DT, Murray CJ. Global Burden of Disease and Risk Factors. Washington: The World Bank; 2006.

Belzer K, Schneier FR. Comorbidity of anxiety and depressive disorders: issues in conceptualization, assessment, and treatment. J Psychiatr Pract. 2004;10(5):296-306.

Kessler RC, Nelson CB, McGonagle KA, Liu J, Swartz M, Blazer DG. Comorbidity of DSM-III-R major depressive disorder in the general population: results from the US National Comorbidity Survey. Br J Psychiatry Suppl. 1996;17-30.

Baldwin DS, Lopes AT. The influence of comorbid anxiety disorders on outcome in major depressive disorder. Medicographia. 2009;31:126-31.

Keller MB, Krystal JH, Hen R, Neumeister A, Simon NM. Untangling depression and anxiety: clinical challenges. J Clin Psychiatry. 2005;66(11):1477-84.

Sánchez C. The pharmacology of citalopram enantiomers: the antagonism by R-citalopram on the effect of S-citalopram. Basic Clin Pharmacol Toxicol. 2006;99(2):91-5.

Thase ME. Managing depressive and anxiety disorders with escitalopram. Expert Opin Pharmacother. 2006;7(4):429-40.

Waugh J, Goa KL. Escitalopram: a review of its use in the management of major depressive and anxiety disorders. CNS Drugs. 2003;17(5):343-62.

McKeage K, Plosker GL. Amisulpride: a review of its use in the management of schizophrenia. CNS Drugs. 2004;18(13):933-56.

Carson WH, Kitagawa H. Drug development for anxiety disorders: new roles for atypical antipsychotics. Psychopharmacol Bull. 2004;38(1):38-45.

Overstreet DH, Knapp DJ, Moy SS, Breese GR. A 5-HT1A agonist and a 5-HT2c antagonist reduce social interaction deficit induced by multiple ethanol withdrawals in rats. Psychopharmacology (Berl). 2003;167(4):344-52.

Tohen M, Vieta E, Calabrese J, Ketter TA, Sachs G, Bowden C, et al. Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Arch Gen Psychiatry. 2003;60(11):1079-88.

Hirschfeld RM, Weisler RH, Raines SR, Macfadden W, BOLDER Study Group. Quetiapine in the treatment of anxiety in patients with bipolar I or II depression: a secondary analysis from a randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2006;67(3):355 62.

Scatton B, Claustre Y, Cudennec A, Oblin A, Perrault G, Sanger DJ, et al. Amisulpride: from animal pharmacology to therapeutic action. Int Clin Psychopharmacol. 1997;12 Suppl 2:S29-36.

Chadda RK. Social support and psychosocial dysfunction in depression. Indian J Psychiatry. 1995;37(3):119-23.

Chaudhury PK, Deka K, Chetia D. Disability associated with mental disorders. Indian J Psychiatry. 2006;48(2):95-101.

Sethi BB, Prakash R. Depression in industrial population. An overview of Indian research in depression. Indian J Psychiatry. 1979;21:359-61.

Ramachandran V, Menon MS, Arunagiri S. Socio-cultural factors in late onset depression. Indian J Psychiatry. 1982;24(3):268-73.

National Institute of Mental Health. Women and Depression, Discovering Hope. Bethesda, MD: US Department of Health and Human Services, National Institute of Health, National Institute of Mental Health; 2009.

Dutta SB, Beg MA, Sindhu S, Singh NK. Role of pharmaco-epidemiology in psychopharmacology: a study in psychiatric out-patient department of a tertiary care teaching hospital at Dehradun, Uttarakhand. Int J Basic Clin Pharmacol. 2014;3(4):637-43.

Grover S, Avasth A, Kalita K, Dalal PK, Rao GP, Chadda RK, et al. IPS multicentric study: antidepressant prescription patterns. Indian J Psychiatry. 2013;55(1):41-5.

Giel R, Harding TW. Psychiatric priorities in developing countries. Br J Psychiatry. 1976;128:513-22.

Gautam SK, Kapur RL. Psychiatric patients with somatic complaints. Indian J Psychiatry. 1977;19:75-80.

Barsky AJ. Amplification, somatisation and the somatoform disorders. Psychosomatics. 1992;33:28-34.

Roberts RE, Lee ES. Occupation and the prevalence of major depression, alcohol, and drug abuse in the United States. Environ Res. 1993;61(2):266-78.

Bose A, Korotzer A, Gommoll C, Li D. Randomized placebo-controlled trial of escitalopram and venlafaxine XR in the treatment of generalized anxiety disorder. Depress Anxiety. 2008;25(10):854-61.

Soares CN, Thase ME, Clayton A, Guico-Pabia CJ, Focht K, Jiang Q, et al. Desvenlafaxine and escitalopram for the treatment of postmenopausal women with major depressive disorder. Menopause. 2010;17(4):700-11.

Hoge EA, Worthington JJ 3rd, Kaufman RE, Delong HR, Pollack MH, Simon NM. Aripiprazole as augmentation treatment of refractory generalized anxiety disorder and panic disorder. CNS Spectr. 2008;13(6):522-7.

Pollack MH, Simon NM, Zalta AK, Worthington JJ, Hoge EA, Mick E, et al. Olanzapine augmentation of fluoxetine for refractory generalized anxiety disorder: a placebo controlled study. Biol Psychiatry. 2006;59(3):211-5.

McIntyre A, Gendron A, McIntyre A. Quetiapine adjunct to selective serotonin reuptake inhibitors or venlafaxine in patients with major depression, comorbid anxiety, and residual depressive symptoms: a randomized, placebo-controlled pilot study. Depress Anxiety. 2007;24(7):487-94.

Simon NM, Hoge EA, Fischmann D, Worthington JJ, Christian KM, Kinrys G, et al. An open-label trial of risperidone augmentation for refractory anxiety disorders. J Clin Psychiatry. 2006;67(3):381-5.

Schoemaker H, Claustre Y, Fage D, Rouquier L, Chergui K, Curet O, et al. Neurochemical characteristics of amisulpride, an atypical dopamine D2/D3 receptor antagonist with both presynaptic and limbic selectivity. J Pharmacol Exp Ther. 1997;280(1):83-97.

Rosenzweig P, Canal M, Patat A, Bergougnan L, Zieleniuk I, Bianchetti G. A review of the pharmacokinetics, tolerability and pharmacodynamics of amisulpride in healthy volunteers. Hum Psychopharmacol. 2002;17(1):1-13.

Gartlehner G, Gaynes BN, Hansen RA, Thieda P, DeVeaugh-Geiss A, Krebs EE, et al. Comparative benefits and harms of second-generation antidepressants: background paper for the American College of Physicians. Ann Intern Med. 2008;149(10):734-50.

Chabra V, Bhatia MS. Amisulpride: a brief review. Delhi Psychiatry J. 2007;10(2):140-3.